Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Cofactor Genomics

Other names: Cofactor Genomics | Cofactor Genomics, Inc. | Cofactor Genomics, Inc | Cofactor Genomics Inc. | Cofactor Genomics Inc
Related tests:


Cofactor Genomics Opens Enrollment for Non-small Cell Lung Cancer Study of OncoPrism Predictive Diagnostic Assay (Businesswire)
"Cofactor Genomics...today announced commencement of a study of its OncoPrism™ assay in non-small cell lung cancer (NSCLC), the second indication being studied in the company’s national PREDAPT study that will ultimately encompass 11 cancers....'We intend to grow our clinical and biomarker team quickly to expedite validation of our lung cancer assay so it will closely follow our head and neck cancer assay in 2023'."
Enrollment open
OncoPrism™ Assay
Cofactor Genomics RNA-seq assay outperforms PD-L1 IHC to predict immunotherapy responders (Precision Oncology News)
"Cofactor Genomics' OncoPrism platform, which combines immune cell quantification and T-cell subtyping, has outperformed PD-L1 testing as a method to identify cancer patients who will respond to immunotherapy...The San Francisco-based company's platform has shown in the PREDAPT trial that it was twice as accurate in identifying which patients would respond to immunotherapy compared to PD-L1 by immunohistochemistry. At a scientific meeting earlier this month, Cofactor reported data from the trial evaluating OncoPrism against standard PD-L1 IHC testing in patients with head and neck cancer, non-small cell lung cancer, and melanoma."
OncoPrism™ Assay
Cofactor Genomics Unveils New Data Showing Novel OncoPrism Diagnostic is Nearly Twice as Accurate as PD-L1 in Identifying Immunotherapy Responders (Cofactor Genomics Press Release)
"Data show that Cofactor's OncoPrism test using Predictive Immune Modeling was nearly twice as accurate as PD-L1 assays in determining patients that will benefit from immunotherapies such as Keytruda (pembrolizumab)....In clinical studies where OncoPrism was tuned to have the same sensitivity as PD-L1, Cofactor’s test reached 75% accuracy in predicting responders to immune checkpoint inhibitors, when compared to 42% accuracy for PD-L1. These interim results from nine healthcare systems show at similar sensitivity, OncoPrism has greater specificity and continues to be superior to single analyte approaches like PD-L1....The study results provide a strong framework and understanding for the other important cancers we will be studying in our broader PREDAPT work, including non-small cell lung cancer (NSCLC)."
Observational data
OncoPrism™ Assay
Keytruda (pembrolizumab)
Cofactor Genomics commences first predictive immune modeling clinical trial to bridge precision medicine gap for immunotherapy (Cofactor Genomics Press Release)
"Cofactor Genomics…today announced commencement of the first multicenter clinical trial of its OncoPrismTM diagnostic assay, using the company’s patented approach to generating multidimensional immune biomarkers... Fifteen hospitals and healthcare networks, including Mayo Clinic, MultiCare Institute for Research and Innovation, and Revive Research Institute, are currently enrolling in the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) Trial to evaluate use of the OncoPrism test in patients with recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) to effectively predict a patient’s response to immunotherapy. The company expects additional sites to join the trial before the end of 2021."
Trial status
OncoPrism™ Assay